Home > Insider Trading > Filing (0001415889-25-003728)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787297	Passage Bio Inc.	PASG	Biological Products, (No Disgnostic Substances) (2836)	822729751

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1987062	Kathleen Borthwick	One Commerce Square 2005 Market Street, 39Th Floor Philadelphia PA 19103	Cfo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-10	8,000	$0.00	44,466	No	4	M	Direct
Common Stock	Disposition	2025-02-11	3,183	$0.53	41,283	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2025-02-10	8,000	$0.00	8,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Includes 4,000 shares acquired on May 16, 2024 and 4,000 shares acquired on November 16, 2024 under the 2020 Employee Stock Purchase Plan.
The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $0.51 to $0.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade.
1/3 of the RSUs vested on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.